Compare Ascendis Pharma A/S (ASND) vs Deckers Outdoor Corp (DECK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Deckers Outdoor Corp — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Deckers Outdoor Corp trades at $106.51 (market cap $14.72B). The key difference: Ascendis Pharma A/S is the larger of the two by market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Deckers Outdoor Corp nearer its low. Which is the better fit depends on your goals.
| ASND | DECK | |
|---|---|---|
Market Cap | $17.74B | $14.72B |
Sector | Health | Consumer Cyclical |
52-Week High | $277.18 | $123.91 |
52-Week Low | $163.32 | $79.54 |
Enterprise Value | $18.11B | $13.19B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
DECK trades at $105.99, up 1.66% today, with a bearish technical signal but strong fundamentals. Revenue grew to $4.99B in 2025, with net income reaching $966M and profit margin expanding to 19.37%. Recent quarters show consistent earnings beats, including Q1 2026 EPS of $0.96 versus $0.83 expected. Cash flow from operations remains robust at $1.04B, supporting financial stability.
The stock offers upside to the $121.50 consensus price target, driven by HOKA and UGG global growth. Risks include competitive pressures and volatile technical indicators. Analyst sentiment is mixed with 41.82% buy ratings, but institutional holdings suggest long-term confidence amid near-term bearish signals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Deckers Outdoor Corp
Deckers Outdoor Corp designs and sells casual and performance footwear, apparel, and accessories. Primary brands include UGG, Teva, and Sanuk. The company distributes Most of its products through its wholesale business, but it also has a substantial direct-to-consumer business with its company-owned retail stores and websites. Most sales are in the United States, although the company also has retail stores and distributors throughout Europe, Asia, Canada, and Latin America. Deckers sources its products from independent manufacturers primarily in Asia.
Read more on DECK →
